tbuckley/cabot-search huggingface dataset:
PTU-098 The UK inflammatory bowel disease audit: key findings from the inpatient experience questionnaire
Authors: K Bodger, I Arnott, C Down, R Driscoll, A Protheroe, M Roughton
Journal: Gut (2012)

<h3>Introduction</h3> The UK IBD Audit seeks to improve the quality and safety of care for IBD patients throughout the UK by auditing individual patient care and provision and organisation of IBD service resources. The inclusion of an inpatient experience questionnaire in the 3rd round of the audit provided the opportunity to obtain direct patient feedback regarding hospital care. <h3>Methods</h3> Teams at participating sites were required to audit a consecutive sample of inpatients with UC and CD. Completion of local clinical data entry for each case triggered the generation of a patient survey comprising a self-completed questionnaire containing items taken from the National Inpatient Survey questionnaire (Picker Institute) with supplementary questions specific to IBD. Aggregated results are presented for all respondents. <h3>Results</h3> <b>Response rate</b>: 33% (data for 2028 adults and 166 children). Results presented as adults [children] where appropriate. <b>Overall care</b> rated as only fair by 7% [6.7% children] and poor by 2.9% [0%]. Overall satisfaction correlated most strongly with rating of how well doctors and nurses worked together. <b>Composite scores</b> across six domains of acute adult care were comparable across all countries (no national differences). Scores for CD were lower than UC in several domains. Scores for <b>consistency and coordination of care</b> and <b>nursing</b> were relatively low compared to general adult inpatients (National Inpatient Survey, 2009). Only 60% of adults [76% children] reported a visit from a specialist nurse. <b>Hospital food</b>: Rated as poor by 20% [11%]; “Too little” food provided was reported by 15% [16%]; “Never” suited to dietary needs by 15% [8%]. No dietician visit in 59% [26%]. <b>Pain management</b>: “Ever in pain?” 85% [83%]; pain “usually severe” 52% [52%]; analgesic medication “not enough” 16% [12%]. At least 1 in 10 reported sub-optimal aspects of <b>discharge information</b> such as lack of information about drug side effects, the danger signs to watch for or how to manage their condition after going home. <h3>Conclusion</h3> There are many positive findings from the UK IBD inpatient survey—over ¾ of adults and children rated care as “very good” or “excellent”. There are areas for potential improvement. Patients place a strong value on co-ordinated care from experienced staff. Greater provision and involvement of IBD nurses at ward level could play a key role in promoting excellent inpatient care. All admitted IBD patients should receive input from specialist multidisciplinary teams experienced in managing these complex disorders. <h3>Competing interests</h3> None declared.
P1188 A CHANGE IN LIFE-STYLE AFTER SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C IN PEOPLE WHO INJECT DRUGS
Authors: M. Maticic, T. Kastelic, P. Kordiš, T. Oblak, A. Kastelic, J. Meglic-Volkar, M. Rajter, J. Prah, T. Kotar, J. Cuk, A.-M. Rebolj-Kodre
Journal: Journal of Hepatology (2014)
OT-05 * H3.3-K27M IS A NEGATIVE PROGNOSTIC MARKER IN THALAMIC PEDIATRIC GLIOMA
Authors: S. Ryall, P. Buczkowicz, R. Krishnatry, A. Arnoldo, P. Steinbok, U. Tabori, C. Hawkins
Journal: Neuro-Oncology (2015)

Pediatric gliomas are the most commonly diagnosed brain cancer in children, accounting for approximately 50% of all cases. Recently, we conducted genome-analysis of diffuse intrinsic pontine glioma (DIPG), which specifically arises in the brainstem. Through this, we identified a histone H3.3 mutation (a lysine-methionine substitution at position 27 [K27M]) in approximately 70% of cases. We then showed that H3.3K27M is a negative prognostic marker for DIPG patients independent of histology. We hypothesized a similar prognostic role for H3.3K27M in thalamic gliomas. Utilizing a newly optimized, ultra-sensitive digital droplet PCR assay, we analyzed 38 radiologically confirmed thalamic gliomas (13 low grade and 25 high grade gliomas). Median survival for patients with high grade thalamic gliomas was 1.35 years vs 8.71 years for low grade thalamic glioma patients. Three (23%) low grade and 11 (44%) high grade gliomas tested positive for the H3.3K27M mutation. 31 patients, clinically annotated for treatment, extent of resection, age and outcome were used to determine the prognostic implications of H3.3-K27M. Kaplan-Meier survival analysis revealed significantly worse overall survival of thalamic glioma patients harbouring the H3.3-K27M mutation versus wild type samples (log rank p < 0.001) with a median survival of 1.04 vs 5.81 years for H3.3K27M vs WT thalamic gliomas, respectively. Multivariate cox analysis demonstrated H3.3K27M mutation status to be independent of WHO grade as a predictor of overall survival with a hazard ratio of 6.5 (95% confidence intervals 1.78-24.4, p = 0.005). These findings provide the first evidence that H3.3K27M status is a negative prognostic indicator for thalamic pediatric glioma. Furthermore, we have optimized a digital droplet PCR assay to assess mutation status in small samples, including formalin-fixed paraffin embedded, with high sensitivity and specificity in a clinical setting.
Ultrastructure of a Mammosomatotrophic and a Nonfunctional Transplantable Pituitary Tumor Induced in Rats by 2,4,6-Trimethylaniline2
Authors: Joseph Kovl, Harold P. Morris
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Ultrastructure of a Mammosomatotrophic and a Nonfunctional Transplantable Pituitary Tumor Induced in Rats by 2,4,6-Trimethylaniline Get access Joseph Kovl, Joseph Kovl Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold P. Morris Harold P. Morris Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 1, July 1976, Pages 197–205, https://doi.org/10.1093/jnci/57.1.197 Published: 01 July 1976 Article history Received: 14 November 1975 Accepted: 16 January 1976 Published: 01 July 1976
Hwa-Byung: a Korean culture-bound syndrome?
Authors: K M Lin
Journal: American Journal of Psychiatry (1983)

The author reports three cases of Hwa-Byung, a Korean folk illness ordinarily understood by patients and families to be a physical affliction despite the fact that its manifestations include both physiological and psychological symptoms. In addition, the patient often recognizes interpersonal conflicts and anger as precipitating factors. In the three cases reported, the patients also identified an epigastric mass that was not present on physical examination. Symptoms were accompanied by a fear of impending death that was not easily dispelled by medical reassurance. The author discusses the role of depression in the symptom formation of Hwa-Byung as well as the treatment implications.
P2-02-03: MAP3K3, Amplified in Human Breast Cancer, Promotes Breast Tumor Progression and Defines Poor Prognosis.
Authors: J Dong
Journal: Cancer Research (2011)

Abstract Gene amplification in the 17q chromosomal region is observed frequently in breast cancers. An integrative bioinformatics analysis nominated MAP3K3 gene, located in 17q23, as a potential therapeutic target in breast cancer. This gene encodes the mitogen-activated protein kinase kinase kinase 3 (MEKK3), but has not yet been associated with cancer-causal genetic aberrations. We found that MAP3K3 was amplified in approximately 8–20% of breast carcinomas, and that its over-expression was an independent prognostic marker for poor outcome with respect to relapse-free and overall survival, especially among the estrogen receptor-positive breast cancer patients. shRNA-mediated knockdown of MAP3K3 expression significantly inhibited cell proliferation and colony formation of MAP3K3-amplified breast cancer cell lines MCF7 and MDA-MB361, and promoted breast cancer cell apoptosis induced by TNFα, TRAIL, or a doxorubicin. In addition, ectopic expression of MAP3K3, in collaboration with Ras, induced colony formation in both primary mouse embryonic fibroblasts and immortalized mammary epithelial cells (MCF-10A). Together, these results suggest that MAP3K3 is a potential biomarker indicating poor prognosis, contributes to resistance to therapy, and is an oncogene in breast carcinogenesis. Therefore, therapeutic targeting of MAP3K3 may be attractive in breast cancer patients with MAP3K3-amplified breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-02-03.
Uterine Fibroids and Evidence-Based Medicine — Not an Oxymoron
Authors: Elizabeth A. Stewart
Journal: New England Journal of Medicine (2012)

The 2011 report from the Agency for Healthcare Research and Quality on comparative management of uterine fibroids noted, "Despite the prevalence and possible complications of uterine fibroids, few published studies examining the effectiveness of treatment strategies exist."1 Few therapies are approved by the Food and Drug Administration (FDA) for fibroids; leuprolide acetate, a gonadotropin-releasing hormone (GnRH) agonist, was approved in 1995 for preoperative treatment of fibroids, with the addition of iron. In the past decade, uterine-artery embolization and magnetic-resonance–guided focused ultrasound surgery have also been therapeutic options. Surgeries for fibroids, especially hysterectomy, still predominate, and fibroids remain the leading cause . . .
DD-08 * PHASE I CANCER CLINICAL TRIAL FOR 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN)
Authors: M. Ware, R. Weiner, P. Friedlander, C. Gordon, Y. Saenger, T. Mahmood, A. Rodgers, G. Bastian, S. Urien, None Lee, R. Morgan
Journal: Neuro-Oncology (2014)

PURPOSE: DM-CHOC-PEN is a poly-chlorinated pyridine cholesteryl carbonate whose MOA is via alkylation of DNA @ N7 – guanine and via oxidative stress. The aims of this clinical trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), pharmacokinetics (PK) of DM-CHOC-PEN and monitor for clinical responses. METHODS: DM-CHOC-PEN was administered as a 3-hr IV infusion once every 21-days to patients with advanced cancer; melanoma (n = 3), colorectal CA (n = 3), breast (n = 3) and glioblastoma multiforme (n = 6). The trial included patients with advanced cancer +/- CNS involvement. The starting dose was 39 mg/m2 with escalations to date up to 111 mg/m2. RESULTS: Twenty-six (26) patients have been treated. The MTD was 2-tiered and defined as 85.8 mg/m2 for patients with liver involvement and 98.7 mg/m2 for patients without liver abnormalities. The most common adverse effects were fatigue (n = 2), liver dysfunction – elevated bilirubin (Gr-3, n = 3; Gr-2, n = 1), ALT/AST (Gr-2, n = 3), alk phos (Gr-2, n = 3) and an allergic reaction (Gr-2, n = 1). Three (3) patients with liver metastasis demonstrated hyperbilirubinemia (Gr-3 SLT) – 2 at the 98.7 mg/m2 and one (1) at the 111 mg/m2 levels Five (5) additional patients with liver disease have been treated at 85.8 mg/m2 level without toxicity. CONCLUSIONS: DM-CHOC-PEN is safe at the presented dose levels and has a favorable PK profile. Eight (8) patients had responses or significant PFS, including 6 with CNS involvement. A Phase II trial has begun in patients with primary brain cancer and brain metastases from melanoma, breast cancer and lung cancer.
Abstract 5039: Comparative analysis of miRNA in hormonal refractory prostate cancer
Authors: Min Jin Lee, Youn Jin Cha, Suki Kang, Wonsik Ham, Young Deuk Choi, Nam Hoon Cho
Journal: Cancer Research (2012)

Abstract Background: Nucleotides 2-7 within mature miRNAs, short RNA molecule of between 19 and 22, create the ‘seed region’ that specifies the specific mRNA. To date, miRNAs have been linked to the etiology, progression and prognosis of cancer. The gain or loss of specific miRNAs can function as an oncogene or tumor suppressor. Design: By using recently developed miRNA 14K array (Agilent), we designed to compare miRNA expression between HRPCa cell line (PC3) and sensitive cell line (LNCaP). As validation for target mRNA following bioinformatics, candidates were applied on the neoadjuvant bicalutamide treated radical prostatectomized specimens using immunohistochemistry. Results: Amongst 57 upregulated miRNAs (ratio &amp;gt;2.0), oncomirs-miRNAs that are amplified or overexpressed in PC3, includes miR-31, -27a, -23a, -9, -100, -29a, -24, let 7i, -21, -221, 29b, -222, -181a. Probable candidates for target mRNAs to each oncomir are tumor suppressor gene family, including p27, PTEN, apoptosis related genes (DAXX, PDCD4, caspase recruitment domain 10/11), ECM adhesion genes (Integrin β4, ADAMTS 7/8), SOCS 6. In 23 downregulated miRNAs (ratio&amp;gt;2.0), tumor suppressor miRNAs that are downregualted or deleted from chromosomes acting as tumor suppressor genes, include miR-141, -200 a/b/c, -148a, -429, -34a, -195, -99a, -203, -125b-2. Possible candidates for target mRNAs are oncogeneic family are EMT-related genes including ZEB1, cell cycle related genes (Wee1, cyclin E1, CDK6), prostate specific proteins (STEAP1, prostein), RTK family (AXL, Rab-38, Rab-9A), transcriptional factor promotion (EIF2, SOX6), mitogen activator (MAP p38), secretory protein (SDF2). Among the top-listed candidates, STEAP1, prostein, ZEB1, and cyclin E1 were relatively overexpressed in the refractory PCa to compare with regressing cancer cells. Conclusion: Complicated networks of miRNA play substantial and crucial roles in the regulation of hormonal refractory prostate cancer, predominantly by virtue of STEAP1, prostein, ZEB1, cyclin E1 overexpression, and suppression of apoptosis-related genes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5039. doi:1538-7445.AM2012-5039
A2.14 CCR6 expression drives arthritis in a T cell dependent manner
Authors: M Bonelli, T Puchner, L Goeschl, S Hayer, B Niederreiter, JS Smolen, C Scheinecker, S Blüml
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Backgrounds and objectives</h3> Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, characterised by synovial infiltration of various inflammatory cells. Chemokines are involved in controlling the recruitment of different cell types into the synovial membrane. Increased production of MIP-3-a and accumulation of CCR6 expressing mononuclear cells can be found in joints of RA patients. CCR6 expression has also been reported on CD4<sup>+</sup> T cells, in particular regulatory as well as Th17 cells. Recent data suggest that CD25<sup>-</sup>Foxp3<sup>+</sup> T cells upregulate CCR6 and promote arthritis. In this study, we investigated the role of CCR6 in the pathogenesis of arthritis using different arthritis models. <h3>Materials and methods</h3> Clinical as well as histological signs of arthritis were investigated in the collagen-induced arthritis (CIA), K/BxN serum transfer arthritis and in the human tumour necrosis factor (hTNFtg) arthritis model, comparing <i>wt</i> and <i>CCR6-/-</i> mice. We analysed the phenotype of lymph node cells by flow cytometry and cytokine concentrations in serum. Anti-collagen antibodies and cytokines were measured by enzyme-linked immunosorbent assay. <h3>Results</h3> Since CCR6 is an important component of the innate immune system we compared the development of arthritis in <i>CCR6-/-</i> mice in 2 different arthritis models known to be T cell independent, the K/BxN serum transfer arthritis and hTNFtg arthritis. In both models, we did not detect any significant differences in clinical signs of inflammation or histological severity of arthritis between wt and CCR6-/- mice. In additon, we could not detect differences in bone density between <i>wt</i> and <i>CCR6-/-</i> mice. To investigate the role of CCR6 as part of the adaptive immune system in the development of arthritis we induced CIA in <i>wt</i> and <i>CCR6-/-</i> mice. <i>CCR6-/-</i> mice were almost completely protected from CIA. Analyses of T cell subsets by flow cytometry revealed a significant reduction of CD25<sup>-</sup>Foxp3<sup>+</sup> T cells. <h3>Conclusions</h3> These data suggest that CCR6 is not crucially involved in innate immunity driven arthritis, but is necessary for the development of autoimmune arthritis. Importantly, CCR6 is necessary for the generation of pathogenic CD25<sup>-</sup>Foxp3<sup>+</sup> T cells in CIA, suggesting an important function of CCR6 on T cells in the development of autoimmune arthritis.
OP0102-HPR Sedentary Behaviour in Danish Patients with Rheumatoid Arthritis - What is the Association to Pain, Fatigue, Sleep and Physical Function? A Cross-Sectional Study
Authors: K. Loeppenthin, B. A. Esbensen, M. Østergaard, P. Jennum, T. Thomsen, J. Midtgaard
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> A growing body of evidence has emerged suggesting that prolonged sedentary behaviour (SB) is a risk factor for poor health and independently associated with both all cause– and cardiovascular mortality. It is furthermore established that rheumatoid arthritis (RA) is associated with pain, fatigue, poor sleep and substantial physical disability. Clinical studies document that physical activity interventions and potentially reduction of prolonged SB may alleviate some of these problems. However, the prevalence and determinants for SB in RA patients is not well investigated. <h3>Objectives</h3> To investigate the prevalence of self-reported SB and its association to pain, fatigue, poor sleep and physical disability. <h3>Methods</h3> A total of 500 RA patients from a rheumatology outpatient clinic were recruited consecutively. Data included self-reported physical activity and SB assessed by the Physical Activity Scale. Other instruments and outcomes included were the Health Assessment Questionnaire, Visual Analogue Scale for pain and fatigue, the Multidimensional Fatigue Inventory and Pittsburgh Sleep Quality Index. Associations were studied with logistic regression analysis categorising patients into three groups: (1) low (Low-SB) (0.5-3 hour per day), (2) moderate (Moderate-SB) (&gt;3-5 hour per day) and (3) high (High-SB) (&gt;5-16 hour per day) SB. <h3>Results</h3> The response rate was 89%. Participants’ mean age was 60 years (range 22 to 88 years). The mean duration of SB was 4.4 hour (SD 2.7) per day. There was no significant association between SB and sex (p=0.37). Furthermore, diabetes was found to be significantly more prevalent for patients in the High-SB group in comparison to Low-SB (14% vs. 1% p&lt;0.0001). After adjusting for age, sex, pain, fatigue, HAQ-score, sleep and disease activity, SB was not found to be associated with pain, MFI subscales general fatigue, mental fatigue, reduced activity, reduced motivation, poor sleep and physical disability. The adjusted analyses showed that high age was associated with more SB, OR 1.05 [95% CI 1.03 – 1.07] for Moderate-SB vs. Low-SB and OR 1.07 [95% CI 1.05 – 1.10] for High-SB vs. Low-SB. The only disease-specific variable associated with SB was MFI subscale physical fatigue OR 1.07 [95% CI 1.01 – 1.14] for Moderate-SB vs. Low-SB and OR 1.22 [95% CI 1.13 – 1.32] for High-SB vs. Low-SB. <h3>Conclusions</h3> SB is prevalent in RA patients. However, the study findings suggest that SB is not associated with pain, general fatigue, mental fatigue, reduced activity, reduced motivation, sleep and physical disability. Further research is needed to properly promote reduced SB in RA patients. <h3>Disclosure of Interest</h3> None Declared
OP0300-PARE Keele University – the Development of A Research User Group and A Structured System to Support Patient Involvement
Authors: C.A. Rhodes, A. Higginbottom
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The Arthritis Research UK Primary Care Centre at Keele University has run a dedicated Research User Group for 8 years. Members have been successfully recruited and supported to get involved in a variety of studies of musculoskeletal pain and arthritis. <h3>Objectives</h3> We describe how the Research User Group has evolved and how members are supported to provide their perspective on living with musculoskeletal pain and arthritis, in both quantitative and qualitative research, through their involvement in different roles within cohort studies, randomised control trials and observations and interviews <h3>Methods</h3> The group has now evolved from an original membership of 8 to over 60 members through a recruitment and selection based on "expertise by experience". Members then become part of subgroups specifically formed to align with the Centre9s research strategy. Dedicated and paid staff, both with experience of living with a long-term condition, have been appointed to support the group. A set of guides has been produced and training workshops developed to help members to be involved in the different stages of the research cycle. <h3>Results</h3> We now have 60 members involved in over 60 different projects. Members have coauthored publications [1], developed quality indicators to measure osteoarthritis care and produced a patient booklet to support osteoarthritis consultations [2] <h3>Conclusions</h3> Our open model of recruitment has succeeded and a structured model of support has helped patient involvement become integral within our research projects. <h3>References</h3> Grime J et al. Developing written information on osteoarthritis for patients. Health Expectations 2011. http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3635
680 Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent
Authors: M.A.M. Berends, J. Snoek, P.C.M. van de Kerkhof, E.M.J.G. de Jong, M.G.H. van Oilen, J.P.H. Drenth
Journal: Journal of Hepatology (2006)